E3 ligases conjugate ubiquitin to specific target proteins, signaling various consequences such as degradation in the proteasome or relocation from one cellular compartment to another. Deubiquitylases (DUBs) cleave ubiquitin from target proteins, including other ubiquitins. Ubiquitin conjugation and deconjugation both have physiological consequences, and both can be manipulated by small molecules for therapeutic effect.
Since 2002, Progenra scientists have been working to understand the intricacies of the ubiquitin pathway to maximize discovery of multiple classes of therapeutic molecule. This work has led to the creation of the UbiPro™ Drug Discovery Platform — a comprehensive toolbox for studying therapeutically relevant DUBs and E3 Ligases and screening our diverse collection of >600,000 drug-like small molecules to discover compounds suitable for clinical trial.